Clinical Trial Update: Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

View source ↗

Summary

A clinical trial update evaluating brain function in Parkinson's disease patients with different genetic characteristics using DaTSCAN imaging (ioflupane I-123)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• DaTSCAN (Ioflupane I-123) (ioflupane I-123)
• Fluorodeoxyglucose (FDG) (Fluorodeoxyglucose)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Parkinson Disease | Status: UNKNOWN